Communique of the Kigali Community Meeting on Dolutegravir and Weight Gain

In this meeting of people living with HIV, participants deliberated on the emerging data on DTG-associated weight gain and hyperglycemia. Based on the data currently available and the balance of these risks and DTG’s benefits – reduced side effects, improved efficacy, and a high barrier to resistance – participants determined unanimously that DTG should remain the preferred first-line regimen and be accessible to all.

Read the Communique